Gonzalez-Serna, AGenebat, MDe-Luna-Romero, MTarancon-Diez, LDominguez-Molina, BPacheco, Y MMuñoz-Fernandez, M ALeal, MRuiz-Mateos, E2023-01-252023-01-252016-09-23Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco YM, et al. Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401.http://hdl.handle.net/10668/10329TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.enHIV tropismMaravirocMonotherapyPhenotypic testVirological responseHIV drug resistanceDiagnostic accuracyCyclohexanesHIVHIV Fusion InhibitorsHumansInhibitory Concentration 50MaravirocTriazolesViral TropismVirologyresearch article27480849Restricted AccessVIHTropismo viralMonoterapiaPruebas fenotípicasResistencia a medicamentos antirretroviralesCarga viralValidación clínica10.1128/AAC.01326-161098-6596PMC5038326https://europepmc.org/articles/pmc5038326?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038326/pdf